For the quarter ending 2026-03-31, RLAY made $3,000K in revenue. -$73,463K in net income. Net profit margin of -2448.77%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 3,000 | 6,999 | 0 | 677 |
| Research and development expenses | 70,563 | 55,415 | 68,262 | 63,897 |
| Change in fair value of contingent consideration liability | - | - | 0 | 0 |
| General and administrative expenses | 11,027 | 12,215 | 12,129 | 13,627 |
| Total operating expenses | 81,590 | 67,630 | 80,391 | 77,524 |
| Loss from operations | -78,590 | -60,631 | -80,391 | -76,847 |
| Interest income | 5,352 | 5,710 | 6,407 | 7,105 |
| Other (expense) income | - | 31 | -165 | -633 |
| Other expense | 53 | - | - | - |
| Total other income, net | 5,299 | 5,741 | 6,242 | 6,472 |
| Net loss | -73,291 | -54,890 | -74,149 | -70,375 |
| Unrealized holding (loss) gain | -172 | 240 | 656 | -201 |
| Total other comprehensive (loss) income | -172 | 240 | 656 | -201 |
| Total comprehensive loss | -73,463 | -54,650 | -73,493 | -70,576 |
| Basic EPS | -0.41 | -0.315 | -0.43 | -0.41 |
| Diluted EPS | -0.41 | -0.403* | -0.43 | -0.41 |
| Basic Average Shares | 179,849,137 | 173,459,246 | 172,389,209 | 171,264,622 |
Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY)